What are the treatment options for orthostatic hypotension in elderly patients or those with a history of chronic diseases?

Treatment of Orthostatic Hypotension

Initial Management: Identify and Remove Reversible Causes

The first and most critical step is to discontinue or switch medications that worsen orthostatic hypotension rather than simply reducing doses. 1, 2 Drug-induced autonomic failure is the most frequent cause of orthostatic hypotension, with diuretics and vasodilators being the primary culprits. 2

High-Risk Medications to Discontinue or Switch:

• Alpha-1 blockers (doxazosin, prazosin, terazosin, tamsulosin) are strongly associated with orthostatic hypotension, especially in older adults 2, 3
• Diuretics cause orthostatic hypotension through volume depletion and are "probably the most frequent cause" overall 2, 3
• Centrally-acting agents (clonidine, methyldopa) 3
• Vasodilators (hydralazine, minoxidil) 3
• Beta-blockers should be avoided unless compelling indications exist 4, 3

Preferred Antihypertensive Alternatives (if blood pressure control still needed):

• Long-acting dihydropyridine calcium channel blockers (amlodipine) are first-line for patients requiring continued antihypertensive therapy 1, 2, 3
• RAS inhibitors (ACE inhibitors or ARBs) have minimal impact on orthostatic blood pressure 1, 2, 3

---

Non-Pharmacological Interventions (First-Line Treatment)

Non-pharmacological approaches should be pursued as first-line treatment for all patients, particularly those with supine hypertension. 1, 2

Volume Expansion:

• Increase fluid intake to 2-3 liters daily unless contraindicated by heart failure 1, 2
• Increase salt intake to 6-9 grams daily if not contraindicated 1, 2
• Acute water ingestion of ≥480 mL provides temporary relief with peak effect at 30 minutes 1, 2

Dietary Modifications:

• Eat smaller, more frequent meals to reduce postprandial hypotension 1, 2
• Avoid large carbohydrate-rich meals 5
• Limit alcohol consumption as it causes both autonomic neuropathy and central volume depletion 2

Physical Maneuvers (Particularly Effective in Patients <60 Years):

• Leg crossing, squatting, stooping, and muscle tensing during symptomatic episodes 1, 2, 6
• Leg muscle pumping/contractions 6
• Bending forward 6
• These maneuvers are most effective when patients have prodromal symptoms 1, 2

Positional Strategies:

• Elevate the head of the bed by 10 degrees during sleep to prevent nocturnal polyuria, maintain favorable fluid distribution, and ameliorate nocturnal hypertension 1, 2
• Advise gradual staged movements with postural changes 1, 2

Compression Garments:

• Use waist-high compression stockings (30-40 mmHg) and abdominal binders to reduce venous pooling 1, 2
• Abdominal compression is particularly effective 6

Physical Conditioning:

• Encourage physical activity and exercise to avoid deconditioning, which worsens orthostatic intolerance 2

---

Pharmacological Treatment (When Non-Pharmacological Measures Fail)

Midodrine is the first-line pharmacological agent with the strongest evidence base, supported by three randomized placebo-controlled trials. 1, 2, 7

First-Line: Midodrine

• Starting dose: 2.5-5 mg three times daily 1, 2, 7
• Titration: Increase up to 10 mg three times daily based on response 1, 2
• Mechanism: Alpha-1 agonist that increases vascular tone through arteriolar and venous constriction 1
• Expected effect: Increases standing systolic BP by 15-30 mmHg for 2-3 hours 1
• CRITICAL TIMING: Last dose must be taken at least 3-4 hours before bedtime (not later than 6 PM) to prevent supine hypertension during sleep 1, 2, 7

Midodrine Monitoring and Precautions:

• Monitor for supine hypertension (BP >200 mmHg systolic possible) 7
• Use cautiously with cardiac glycosides, beta blockers, or other agents that reduce heart rate 7
• Use cautiously in patients with urinary retention, diabetes, or visual problems 7
• Starting dose should be 2.5 mg in patients with renal impairment 7

Second-Line or Combination: Fludrocortisone

Fludrocortisone is recommended as an alternative or addition for refractory cases. 1, 2

• Starting dose: 0.05-0.1 mg once daily 1, 2
• Titration: Increase to 0.1-0.3 mg daily based on response (maximum 1.0 mg daily) 1, 2
• Alternative loading approach: 0.2 mg loading dose followed by 0.1 mg daily maintenance 2
• Mechanism: Mineralocorticoid that acts through sodium retention and vessel wall effects 1, 2

Fludrocortisone Monitoring Requirements:

• Check for supine hypertension (most important limiting factor) 2
• Monitor for hypokalemia due to mineralocorticoid effects 1, 2
• Monitor for congestive heart failure and peripheral edema 1, 2
• Check electrolytes periodically 2

Fludrocortisone Contraindications:

• Avoid in active heart failure or significant cardiac dysfunction 1, 2
• Avoid in pre-existing supine hypertension 1, 2
• Avoid in severe renal disease where sodium retention would be harmful 2

Combination Therapy for Refractory Cases:

For non-responders to monotherapy, consider combining midodrine and fludrocortisone as they work through complementary mechanisms (alpha-1 adrenergic stimulation vs. sodium retention). 2

Alternative Agents:

• Droxidopa is FDA-approved and particularly effective for neurogenic orthostatic hypotension in Parkinson's disease, pure autonomic failure, and multiple system atrophy 1, 2
• Pyridostigmine may be beneficial for refractory neurogenic orthostatic hypotension with a favorable side effect profile (fewer side effects than fludrocortisone) 2, 8

---

Treatment Goals and Monitoring

The therapeutic objective is minimizing postural symptoms and improving functional capacity, NOT restoring normotension. 1, 2

Diagnostic Confirmation:

• Measure BP after 5 minutes of sitting/lying, then at 1 and/or 3 minutes after standing 1, 2
• A drop of ≥20 mmHg systolic or ≥10 mmHg diastolic confirms orthostatic hypotension 1

Ongoing Monitoring:

• Obtain lying and standing BPs periodically in all hypertensive individuals over 50 years old 4
• Monitor for supine hypertension development which can cause end-organ damage 2
• Reassess within 1-2 weeks after medication changes 2
• Continue midodrine only for patients who report significant symptomatic improvement 7

---

Special Considerations for Elderly Patients

Intensive blood pressure lowering does not increase the risk of orthostatic hypotension or falls in elderly patients. 1

Asymptomatic orthostatic hypotension during hypertension treatment should NOT trigger automatic down-titration of therapy. 1

For patients aged ≥85 years or those with moderate-to-severe frailty requiring both hypertension treatment and orthostatic hypotension management, long-acting dihydropyridine calcium channel blockers or RAS inhibitors are preferred first-line agents. 1, 3

---

Critical Pitfalls to Avoid

• Do NOT simply reduce the dose of offending medications—switch to alternatives 2
• Do NOT administer midodrine after 6 PM to prevent nocturnal supine hypertension 2, 7
• Do NOT use fludrocortisone in patients with heart failure or supine hypertension 2
• Do NOT combine multiple vasodilating agents (ACE inhibitors + calcium channel blockers + diuretics) without careful monitoring 2
• Do NOT overlook volume depletion as a contributing factor 2
• Do NOT withhold treatment based on age alone—there is no definitive evidence of increased risk unless DBP is lowered to 55-60 mmHg 4